The less time they give Boston Scientific, the worse it is for Boston Scientific. They have less time to react.
There was nothing in the earnings report that would renew investor interest.
There's a lot of frustration among institutional shareholders and employees who own the stock.
If the relationship has been adversarial, the FDA, we believe, would not be as accommodating, even in speech.
I have a feeling that Temecula is pretty safe.
It's still a possibility. But the valuation is high, and one thing we learnt from the J&J bid for Guidant is they are very sensitive to valuation.
It's still a possibility. But the valuation is high, and one thing we learned from the J&J bid for Guidant is they are very sensitive to valuation.
I think they (St. Jude) definitely look like they are in play. They certainly would be an attractive candidate.
I think they easily could go up to $76 without a lot of damage.
I certainly think it could be a stand-alone company. I'm not certain it should be.
